Pentam 300
- Generic Name: pentamidine isethionate for injection
- Brand Name: Pentam 300
Pentam 300(Pentamidine Isethionate for Injection) side effects drug center
- Related Drugs
- Drug Comparison
- impaired kidney function,
- elevated serum creatinine,
- injection site reactions (abscess, tissue death, pain, or a hard lump),
- low white blood cell count (leukopenia),
- elevated liver function tests,
- high levels of nitrogen in the blood,
- loss of appetite,
- nausea,
- elevated blood urea nitrogen,
- low blood sugar (hypoglycemia),
- low blood pressure (hypotension),
- rash,
- low blood platelets,
- confusion/hallucinations,
- bad taste in mouth, and
- anemia
- wheezing, choking, or other breathing problems after using this medication with a nebulizer;
- a light-headed feeling, like you might pass out;
- fast or uneven heart rate;
- painful or difficult urination;
- confusion, hallucinations;
- pain, burning, irritation, or skin changes where the injection was given;
- worsening symptoms, or signs of a new infection (fever, cough, trouble breathing, night sweats);
- a blood cell disorder--pale skin, feeling light-headed or short of breath, easy bruising, unusual bleeding, purple or red pinpoint spots under your skin;
- pancreatitis--severe pain in your upper stomach spreading to your back, nausea and vomiting;
- low blood sugar--headache, hunger, weakness, sweating, confusion, irritability, dizziness, or feeling jittery; or
- severe skin reaction--fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
- loss of appetite; or
- unusual or unpleasant taste in the mouth.
What Is Pentam 300?
Pentam 300 (pentamidine isethionate for injection) is an anti-protozoal drug is indicated for the treatment of pneumonia due to Pneumocystis carinii.
What Are Side Effects of Pentam 300?
Common side effects of Pentam 300 include:
Dosage for Pentam 300
The recommended regimen of Pentam 300 for adults and pediatric patients beyond 4 months of age is 4 mg/kg once a day for 14 to 21 days.
What Drugs, Substances, or Supplements Interact with Pentam 300?
Pentam 300 may interact with other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin.
Pentam 300 During Pregnancy and Breastfeeding
Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Pentam 300; it is unknown how it would affect a fetus. It is unknown if Pentam 300 passes into breast milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding while using Pentam 300 is not recommended.
Additional Information
Our Pentam 300 (pentamidine isethionate for injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
Common side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Pentam 300 (Pentamidine Isethionate for Injection)
SIDE EFFECTS
Caution
Fatalities due to severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes. Nephrotoxic events (increased creatinine, impaired renal function, azotemia, and renal failure) are common with the parenteral administration of pentamidine isethionate. The administration of the drug should, therefore, be limited to the patients in whom Pneumocystis carinii has been demonstrated.
The most frequently reported spontaneous adverse events (1 to 30%) reported in clinical trials, regardless of their relation to pentamidine isethionate therapy were as follows (n=424):
| Cardiovascular: | |
| Hypotension | 5.0% |
| Gastrointestinal: | |
| Anorexia/Nausea | 5.9% |
| Hematologic: | |
| Anemia | 1.2% |
| Leukopenia | 10.4% |
| Thrombocytopenia | 2.6% |
| Hepatic: | |
| Elevated liver function tests | 8.7% |
| Metabolic: | |
| Hypoglycemia | 5.9% |
| Neurologic: | |
| Confusion/hallucinations | 1.7% |
| Skin: | |
| Sterile abscess and/or necrosis, pain, or induration at the site of IM injection | 11.1% |
| Rash | 3.3% |
| Special Senses: | |
| Bad taste | 1.7% |
| Urogenital: | |
| Azotemia | 8.5% |
| Elevated serum creatinine | 23.6% |
| Elevated blood urea nitrogen | 6.6% |
| Impaired renal function | 28.8% |
Adverse events with a frequency of less than 1% incidence were as follows (No causal relationship to treatment has been established for these adverse events):
| Body as a whole: | Allergic reaction (i.e. urticaria, itching, rash), anaphylaxis, arthralgia, chills, extrapulmonary pneumocystosis, headache, night sweats, and Stevens-Johnson syndrome. |
| Cardiovascular: | Abnormal ST segment of electrocardiogram, cardiac arrhythmias, cerebrovascular accident, hypertension, palpitations, phlebitis, syncope, tachycardia, vasodilatation, vasculitis and ventricular tachycardia. |
| Gastrointestinal: | Abdominal pain, diarrhea, dry mouth, dyspepsia, hematochezia, hypersalivation, melena, pancreatitis, splenomegaly, and vomiting. |
| Hematological: | Defibrination, eosinophilia, neutropenia, pancytopenia, and prolonged clotting time. |
| Hepatic: | Hepatic dysfunction, hepatitis and hepatomegaly |
| Metabolic: | Hyperglycemia, hyperkalemia, hypocalcemia, and hypomagnesemia. |
| Neurological: | Anxiety, confusion, depression, dizziness, drowsiness, emotional lability, hypesthesia, insomnia, memory loss, neuropathy, nervousness, neuralgia, paranoia, paresthesia, peripheral neuropathy, seizure, tremors, unsteady gait, and vertigo. |
| Respiratory system: | Asthma, bronchitis, bronchospasm, chest congestion, chest tightness, coryza, cyanosis, eosinophilic or interstitial pneumonitis, gagging, hemoptysis, hyperventilation, laryngitis, laryngospasm, non-specific lung disorder, nasal congestion, pleuritis, pneumothorax, rales, rhinitis, shortness of breath, and tachypnea. |
| Skin: | Desquamation, dry and breaking hair, dry skin, erythema, dermatitis, pruritus, rash, and urticaria. |
| Special senses: | Blepharitis, blurred vision, conjunctivitis, contact lens discomfort, eye pain or discomfort, loss of hearing, loss of taste, and loss of smell. |
| Urogenital: | Flank pain, hematuria, incontinence, nephritis, renal dysfunction and renal failure. |
From post-marketing clinical experience with pentamidine isethionate, the following adverse events have been reported: cough, diabetes mellitus/ketoacidosis, dyspnea, infiltration (extravasation–see WARNINGS), and torsades de pointes.
Read the entire FDA prescribing information for Pentam 300 (Pentamidine Isethionate for Injection)
© Pentam 300 Patient Information is supplied by Cerner Multum, Inc. and Pentam 300 Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.